CX3CL1 and cancer: Doses of 1 ng, 10 ng or 100 ng of murine rCX3CL1 were added to the non-immunogenic dose of MTX-treated cancer cells to analyse whether the addition of CX3CL1 can enhance the immunogenicity of dying cancer cells (Figure 2C).